CYTOKINETICS INCORPOR

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 16:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CYTOKINETICS INCORPORATED - COMMON STOCK

02 Jan 2024 10:11:41 By NetDania Notify

NetDania - New 12 months High: CYTOKINETICS INCORPORATED - COMMON STOCK

29 Dec 2023 11:14:15 By NetDania Notify

NetDania - New 12 months High: CYTOKINETICS INCORPORATED - COMMON STOCK

28 Dec 2023 09:45:29 By NetDania Notify

NetDania - New 12 months High: CYTOKINETICS INCORPORATED - COMMON STOCK

27 Dec 2023 09:45:16 By NetDania Notify

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

27 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

26 Dec 2023 16:00:11 By Nasdaq GlobeNewswire

Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND

07 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND

29 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

03 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Reports Third Quarter 2023 Financial Results

02 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in Upcoming Investor Conferences

01 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Announce Third Quarter Results on November 2, 2023

23 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

19 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions

06 Oct 2023 12:45:00 By Nasdaq GlobeNewswire

Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023

05 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

03 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

02 Oct 2023 16:00:00 By Nasdaq GlobeNewswire